ClinicalTrials.gg
CompletedNCT03365947Updated Oct 22, 2025Results posted

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

A Phase 1/2 interventional study of ARO-HBV and Sterile Normal Saline (0.9% NaCl) in Hepatitis B, sponsored by Arrowhead Pharmaceuticals. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Arrowhead Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Hepatitis B with a site in Australia — 6 open to participants now, 9 under way, none of them phase 3. Hepatitis B · Australia.

Enrollment
21st of 42
114 · median 103
Started
2018
with 2 others
Phase 1/2
2 of 50
none open now
Registered
29th of 50
by date
Lead sponsor
3 of 50
Arrowhead Pharmaceuticals

Among the 50 studies in Hepatitis B with a site in Australia, this one is the 21st largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 1/2, and was the 29th registered.

Hepatitis B

1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 50 studies in Hepatitis B with a site in Australia are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hepatitis B with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).

03

Conditions studied

  • Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of must have a negative pregnancy test, cannot be breast feeding, and must be willing to use .
  • Willing to provide written and comply with study requirements

Additional Inclusion Criteria for Part B:

  • Diagnosis of chronic infection
  • Hepatitis B surface antigen (HbsAg) at screening > or = 50 IU/mL
  • Liver Elastography score \< or = 10.5

Exclusion criteria

Exclusion Criteria:

  • health concerns (with the exception of for Patients in Part B)
  • Abnormal for any clinical safety laboratory result considered clinically significant
  • Regular use of alcohol within 1 month prior to screening
  • Recent use of illicit drugs
  • Use of an agent or device within 30 days prior to dosing or current participation in an investigational study

NOTE: additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    ARO-HBV 35 mg

    Single dose of ARO-HBV 35 mg subcutaneous (sc) injection in normal healthy volunteers

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 100 mg

    Single dose of ARO-HBV 100 mg sc injection in normal healthy volunteers

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 200 mg

    Single dose of ARO-HBV 200 mg sc injection in normal healthy volunteers

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 300 mg

    Single dose of ARO-HBV 300 mg sc injection in normal healthy volunteers

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 400 mg

    Single dose of ARO-HBV 400 mg sc injection in normal healthy volunteers

    Drug: ARO-HBV

  • Placebo comparator
    Placebo

    Sterile normal saline (0.9% NaCl) sc injection in normal healthy volunteers

    Other: Sterile Normal Saline (0.9% NaCl)

  • Experimental
    ARO-HBV 25 mg, Q28D

    ARO-HBV 25 mg sc injection every 28 days (Q28D) in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 50 mg Q28D

    ARO-HBV 50 mg sc injection Q28D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 100 mg Q28D

    ARO-HBV 100 mg sc injection Q28D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 200 mg Q28D

    ARO-HBV 200 mg sc injection Q28D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 300 mg Q28D

    ARO-HBV 300 mg sc injection Q28D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 400 mg Q28D

    ARO-HBV 400 mg sc injection Q28D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 100 mg Q14D

    ARO-HBV 100 mg sc injection every 14 days (Q14D) in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 100 mg Q7D

    ARO-HBV 100 mg sc injection every 7 days (Q7D) in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 300 mg, Q28D, HBeAg+/ Trt Naïve

    ARO-HBV 300 mg sc injection Q28D in hepatitis B e antigen positive/treatment naïve (HBeAg+/Trt Naïve) participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 300 mg, Q28D, HBeAg+/ NUC

    ARO-HBV 300 mg sc injection Q28D in HBeAg+/nucleotide or nucleoside analog treated (HBeAg+/NUC) participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 200 mg, Q7D

    ARO-HBV 200 mg sc injection Q7D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 300 mg, Q7D

    ARO-HBV 300 mg sc injection Q7D in participants with chronic hepatitis B

    Drug: ARO-HBV

  • Experimental
    ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg

    ARO-HBV 200 mg sc injection Q28D plus JNJ-56136379 250 mg in participants with chronic hepatitis B

    Drug: ARO-HBV · Drug: JNJ-56136379

Interventions

  • DrugARO-HBV

    sc injection

  • OtherSterile Normal Saline (0.9% NaCl)

    sc injection

  • oral tablets

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment

    An adverse event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Assessment of causality utilized 3 possible categories: not related, possibly related and probably related.

    Time frame: NHV participants: up to Day 29 (± 2 days); CHB participants: Day 113 (± 2 days)

Secondary outcomes

  1. Part A, Pharmacokinetics (PK) of ARO-HBV Analytes: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  2. Part A, PK of ARO-HBV Analytes : Time to Maximum Plasma Concentration (Tmax)

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  3. Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 hours post-dose

  4. Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  5. Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUC0-t)

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  6. Part A, PK of ARO-HBV Analytes: Terminal Elimination Half-Life (t½)

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  7. Part A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-24

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 hours post-dose

  8. Part A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-t

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  9. Part A, PK of ARO-HBV Analytes: Dose-Normalized Cmax

    Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose

  10. Change From Baseline in HBV Surface Antigen (HBsAg) From Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV

    Time frame: Part B (multiple-ascending dose [MAD] phase) only: up to 113 days

07

Results

Posted Jun 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg, Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mg
Started444441088888844444412
Completed44444988888844444412
Not completed0000010000000000000
Withdrew: Lost to follow-up0000010000000000000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment

An adverse event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Assessment of causality utilized 3 possible categories: not related, possibly related and probably related.

Time frame:
NHV participants: up to Day 29 (± 2 days); CHB participants: Day 113 (± 2 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment
ParticipantsARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mg
Possibly Related TEAE1111152211530220000
Probably Related TEAE0001001001220021020
SecondaryPart A, Pharmacokinetics (PK) of ARO-HBV Analytes: Maximum Observed Plasma Concentration (Cmax)
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Mean · ng/mL
Part A, Pharmacokinetics (PK) of ARO-HBV Analytes: Maximum Observed Plasma Concentration (Cmax)
ng/mLARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-73763976160 ± 106536 ± 3901320 ± 3312920 ± 16704280 ± 1340
Analyte: JNJ-7376392443.0 ± 25.8117 ± 45.2363 ± 89.5827 ± 4471010 ± 398
SecondaryPart A, PK of ARO-HBV Analytes : Time to Maximum Plasma Concentration (Tmax)
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Median · hours
Part A, PK of ARO-HBV Analytes : Time to Maximum Plasma Concentration (Tmax)
hoursARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-737639766.00 (6.00 to 6.03)6.00 (3.00 to 6.00)6.00 (2.00 to 6.00)6.03 (2.00 to 6.05)6.00 (6.00 to 6.00)
Analyte: JNJ-737639246.00 (2.00 to 6.00)6.00 (2.00 to 6.00)1.50 (0.500 to 6.00)2.02 (1.00 to 3.00)6.00 (6.00 to 6.00)
SecondaryPart A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 hours post-dose
Reported as:
Mean · h*ng/mL
Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)
h*ng/mLARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-767639761830 ± 11905480 ± 254017800 ± 418035500 ± 1720044600 ± 15100
Analyte: JNJ-76763924327 ± NA1250 ± 3304320 ± 9658140 ± 31609720 ± 3680
SecondaryPart A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Mean · h*ng/mL
Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)
h*ng/mLARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-6763976—5820 ± NA12600 ± NA14800 ± NA—
Analyte: JNJ-76763924365 ± NA1530 ± NA4610 ± 11908170 ± 3420—
SecondaryPart A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUC0-t)
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Mean · h*ng/mL
Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUC0-t)
h*ng/mLARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-767639761830 ± 11905740 ± 248020100 ± 525037900 ± 1690046900 ± 17400
Analyte: JNJ-76763924254 ± 1271250 ± 3304600 ± 11308330 ± 28209940 ± 3990
SecondaryPart A, PK of ARO-HBV Analytes: Terminal Elimination Half-Life (t½)
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Mean · hours
Part A, PK of ARO-HBV Analytes: Terminal Elimination Half-Life (t½)
hoursARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-6763976—6.45 ± NA5.83 ± NA9.16 ± NA—
Analyte: JNJ-767639247.52 ± NA5.97 ± NA6.48 ± 1.236.02 ± 2.34—
SecondaryPart A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-24
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 hours post-dose
Reported as:
Mean · h*ng/mL/mg
Part A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-24
h*ng/mL/mgARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: NJ-7676397652.1 ± 34.154.8 ± 25.488.9 ± 20.9118 ± 57.3111 ± 37.7
Analyte: JNJ-67639249.34 ± NA12.5 ± 3.3021.6 ± 4.8327.1 ± 10.524.3 ± 9.20
SecondaryPart A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-t
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Mean · h*ng/mL/mg
Part A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-t
h*ng/mL/mgARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-676397652.1 ± 34.157.4 ± 24.8101 ± 26.3126 ± 56.5117 ± 43.5
Analyte:JNJ-767639247.25 ± 3.6312.5 ± 3.3023.0 ± 5.6527.8 ± 9.3924.8 ± 9.98
SecondaryPart A, PK of ARO-HBV Analytes: Dose-Normalized Cmax
Time frame:
Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Reported as:
Mean · ng/mL/mg
Part A, PK of ARO-HBV Analytes: Dose-Normalized Cmax
ng/mL/mgARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mg
Analyte: JNJ-767639764.56 ± 3.035.36 ± 3.906.58 ± 1.659.72 ± 5.5810.7 ± 3.34
Analyte: JNJ-767639241.23 ± 0.7371.17 ± 0.4521.81 ± 0.4482.76 ± 1.492.53 ± 0.994
SecondaryChange From Baseline in HBV Surface Antigen (HBsAg) From Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV
Time frame:
Part B (multiple-ascending dose [MAD] phase) only: up to 113 days
Reported as:
Mean · IU/mL
Change From Baseline in HBV Surface Antigen (HBsAg) From Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV
IU/mLARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mg
Change From Baseline in HBV Surface Antigen (HBsAg) From Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV-1.083 ± 0.5320-1.199 ± 0.2525-1.695 ± 0.4921-1.769 ± 0.4018-1.534 ± 0.3080-1.889 ± 0.6948-1.549 ± 0.2956-1.412 ± 0.4153-2.252 ± 1.0177-2.492 ± 0.6493-2.316 ± 0.6979-1.879 ± 0.2676-1.687 ± 0.3887

Adverse events

Collected over From the screening period (Day -60) and up to the end of the follow-up of the study (Day 398). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARO-HBV 35 mg0/4 (0%)0/4 (0%)1/4 (25%)
ARO-HBV 100 mg0/4 (0%)0/4 (0%)4/4 (100%)
ARO-HBV 200 mg0/4 (0%)0/4 (0%)3/4 (75%)
ARO-HBV 300 mg0/4 (0%)0/4 (0%)3/4 (75%)
ARO-HBV 400 mg0/4 (0%)0/4 (0%)3/4 (75%)
Placebo0/10 (0%)0/10 (0%)8/10 (80%)
ARO-HBV 25 mg Q28D0/8 (0%)0/8 (0%)6/8 (75%)
ARO-HBV 50 mg Q28D0/8 (0%)0/8 (0%)6/8 (75%)
ARO-HBV 100 mg Q28D0/8 (0%)1/8 (12.5%)5/8 (62.5%)
ARO-HBV 200 mg Q28D0/8 (0%)0/8 (0%)4/8 (50%)
ARO-HBV 300 mg Q28D0/8 (0%)0/8 (0%)6/8 (75%)
ARO-HBV 400 mg Q28D0/8 (0%)1/8 (12.5%)7/8 (87.5%)
ARO-HBV 100 mg Q14D0/4 (0%)0/4 (0%)3/4 (75%)
ARO-HBV 100 mg Q7D0/4 (0%)0/4 (0%)4/4 (100%)
ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve0/4 (0%)0/4 (0%)3/4 (75%)
ARO-HBV 300 mg, Q28D, HBeAg+/NUC0/4 (0%)0/4 (0%)2/4 (50%)
ARO-HBV 200 mg, Q7D0/4 (0%)0/4 (0%)4/4 (100%)
ARO-HBV 300 mg, Q7D0/4 (0%)1/4 (25%)3/4 (75%)
ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg0/12 (0%)1/12 (8.3%)3/12 (25%)
Most frequent serious events
Most frequent serious events
EventARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mg
HyperparathyroidismEndocrine disorders0/40/40/40/40/40/100/80/80/80/80/80/80/40/40/40/40/41/40/12
AnxietyPsychiatric disorders0/40/40/40/40/40/100/80/80/80/80/81/80/40/40/40/40/40/40/12
DepressionPsychiatric disorders0/40/40/40/40/40/100/80/80/80/80/81/80/40/40/40/40/40/40/12
MenorrhagiaReproductive system and breast disorders0/40/40/40/40/40/100/80/81/80/80/80/80/40/40/40/40/40/40/12
Retroperitoneal massGastrointestinal disorders0/40/40/40/40/40/100/80/80/80/80/80/80/40/40/40/40/40/41/12
Most frequent other events
Showing 10 of 146
Most frequent other events
EventARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mg
Upper respiratory tract infectionInfections and infestations1/41/40/40/41/42/101/83/80/83/82/84/81/41/41/41/43/40/42/12
NauseaGastrointestinal disorders0/41/41/42/40/41/100/80/80/80/81/80/80/40/40/40/40/41/40/12
FatigueGeneral disorders0/40/42/40/40/41/101/81/81/80/80/81/80/40/40/40/40/40/40/12
HeadacheNervous system disorders1/42/41/41/42/42/100/81/80/80/83/81/80/41/40/40/41/41/40/12
Blood creatine phosphokinase increasedInvestigations0/40/40/40/40/40/101/80/80/80/81/80/80/42/41/40/40/40/40/12
Back painMusculoskeletal and connective tissue disorders0/40/40/40/40/41/100/81/80/80/81/80/80/42/41/40/40/40/40/12
AcneSkin and subcutaneous tissue disorders0/40/40/40/40/40/100/80/80/80/80/80/80/40/42/40/40/40/40/12
Abdominal painGastrointestinal disorders0/41/40/40/40/41/100/80/80/81/81/80/80/40/40/40/40/40/40/12
Abdominal pain lowerGastrointestinal disorders0/40/41/40/40/40/100/80/80/80/80/80/80/40/40/40/40/40/40/12
Abdominal pain upperGastrointestinal disorders1/41/40/40/40/40/100/80/80/80/80/81/80/40/40/40/40/41/40/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)ARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mgTotal
Mean22.0 ± 3.0123.5 ± 0.6724.8 ± 4.2328.1 ± 8.1523.6 ± 3.7327.2 ± 9.0842.8 ± 7.1747.8 ± 6.9750.8 ± 12.4847.5 ± 6.7552.1 ± 7.4241.0 ± 9.9148.9 ± 7.7140.7 ± 6.5931.8 ± 7.9036.0 ± 4.9353.2 ± 6.6750.7 ± 12.3944.9 ± 9.1940.3 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)ARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mgTotal
Female221326322302112231442
Male223124566586332213872
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARO-HBV 35 mgARO-HBV 100 mgARO-HBV 200 mgARO-HBV 300 mgARO-HBV 400 mgPlaceboARO-HBV 25 mg Q28DARO-HBV 50 mg Q28DARO-HBV 100 mg Q28DARO-HBV 200 mg Q28DARO-HBV 300 mg Q28DARO-HBV 400 mg Q28DARO-HBV 100 mg Q14DARO-HBV 100 mg Q7DARO-HBV 300 mg, Q28D, HBeAg+/Trt NaïveARO-HBV 300 mg, Q28D, HBeAg+/NUCARO-HBV 200 mg, Q7DARO-HBV 300 mg, Q7DARO-HBV 200 mg Q28D + JNJ-56136379 250 mgTotal
American Indian or Alaska Native00000000000000000000
Asian0310016688563134431274
Native Hawaiian or Other Pacific Islander100100120021131000013
Black or African American00000010000100000103
White303338000010000000021
More than one race00000000000000000000
Unknown or Not Reported01001100000000000003
08

Study locations

7 sites
  • Research Site 5
    Camperdown, New South Wales 2050, Australia
  • Research Site 4
    Clayton, Victoria 3168, Australia
  • Research Site 3
    Melbourne, Victoria 3065, Australia
  • Research Site 6
    Nedlands, Western Australia 6009, Australia
  • Research Site 7
    Hong Kong, Hong Kong
  • Research Site 1
    Grafton, Auckland 1010, New Zealand
  • Research Site 2
    Papatoetoe, Auckland 2025, New Zealand
09

References and documents

Publications

  • Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Ka-Ho Wong D, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022 Nov;77(5):1287-1298. doi: 10.1016/j.jhep.2022.07.010. Epub 2022 Jul 20. PubMed 35870702 ↗
  • Gane E, Yuen MF, Kakuda TN, Ogawa T, Takahashi Y, Goeyvaerts N, Lonjon-Domanec I, Vaughan T, Schluep T, Hamilton J, Njumbe Ediage E, Hillewaert V, Snoeys J, Lenz O, Talloen W, Biermer M. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antivir Ther. 2022 Jun;27(3):13596535221093856. doi: 10.1177/13596535221093856. PubMed 35695169 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Apr 2020, 24 months.

Results were first posted in Jun 2024, 4 years 1 month after primary completion. A results delay was requested in Apr 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2017
First posted
Dec 8, 2017
StartActual
Mar 27, 2018
Primary completionActual
Apr 23, 2020
CompletionActual
Apr 23, 2020
Results delay requested
Apr 22, 2021
Results first posted
Jun 4, 2024
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03365947
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Mar 27, 2018
Primary completion
Apr 23, 2020
Completion
Apr 23, 2020
Results posted
Jun 4, 2024
Last update
Oct 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion